The amplification of chromosome 1q32—leading to gains in the function of the MDM4 gene, which, in turn, inhibit TP53-mediated transcriptional transactivation—represents another mechanism of TP53-pathway dysfunction leading to MPN-BP. This evidence concerns the gene TP53 and myeloproliferative disorder.